Interaction Checker

Four additional cancer drugs now available on the interaction checker

Thursday 31 August 2017

Imatinib, olaparib, olaratumab and regorafenib are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.

  • Imatinib (Glivec®, Gleevec®, Nibix®, Glimatin®, Imakrebin®, Leutipol®, Tilbaldix®, Mytib® ) is a protein kinase inhibitor and is indicated for the treatment of BCR-ABL positive chronic myeloid leukemia, dermatofibrosarcoma, gastrointestinal stromal tumours and precursor cell lymphoblastic leukemia-lymphoma.
  • Olaparib (Lynparza®) is a PARP inhibitor and is indicated for the treatment of ovarian neoplasms.
  • Olaratumab (Lartruvo®) is a monoclonal antibody and is indicated for the treatment of soft tissue sarcoma.
  • Regorafenib (Stivarga®) is a protein kinase inhibitor and is indicated for the treatment of colorectal neoplasms and gastrointestinal stromal tumours. 
ENDORSED BY
Bopa